# Sandra Navarra

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandra-navarra/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,348 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 38 |
| i10-index | 66 |
| Last Known Institution | University of Santo Tomas Hospital |
| OpenAlex ID | https://openalex.org/A5023220117 |
| ORCID iD | 0000-0003-0094-8654 |
| Works | 185 |

## Researcher papers

- [Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-belimumab-in-patients-with-active-systemic-lupus/)
- [EULAR recommendations for the management of systemic lupus erythematosus: 2023 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023/)
- [Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)](https://scholariq.org/papers/definition-and-initial-validation-of-a-lupus-low-disease-activity-state-lldas/)
- [Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials](https://scholariq.org/papers/effects-of-belimumab-a-b-lymphocyte-stimulator-specific-inhibitor-on-disease/)
- [Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: Prevalence, incidence, clinical features, and mortality](https://scholariq.org/papers/systematic-review-of-the-epidemiology-of-systemic-lupus-erythematosus-in-the/)
- [2021 DORIS definition of remission in SLE: final recommendations from an international task force](https://scholariq.org/papers/2021-doris-definition-of-remission-in-sle-final-recommendations-from-an/)
- [A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)](https://scholariq.org/papers/a-framework-for-remission-in-sle-consensus-findings-from-a-large-international/)
- [A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis](https://scholariq.org/papers/a-randomized-controlled-double-blind-study-comparing-the-efficacy-and-safety-of/)
- [Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study](https://scholariq.org/papers/secukinumab-improves-active-psoriatic-arthritis-symptoms-and-inhibits/)
- [Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial](https://scholariq.org/papers/efficacy-and-safety-profile-of-treatment-with-etoricoxib-120-mg-once-daily/)
- [Disease-specific quality of life in patients with lupus nephritis](https://scholariq.org/papers/disease-specific-quality-of-life-in-patients-with-lupus-nephritis/)
- [The 2024 <scp>APLAR</scp> Consensus on the Management of Lupus Nephritis](https://scholariq.org/papers/the-2024-scp-aplar-scp-consensus-on-the-management-of-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [University of Santo Tomas Hospital](https://scholariq.org/institutions/university-of-santo-tomas-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.